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Host immunityAbstract Background: C3 complement plays a pivotal role in the complement cascade, subserves
several critical functions in human immune response and enhancing bacterial killing and its levels
correlate with infectious diseases. However, the association of C3 with recurrent urinary tract infec-
tion (UTI) is still debatable.
Aim: The aim of this study was to assess the correlation of serum C3 levels and recurrent UTI
among young women.
Materials and methods: Thirty-four recurrent UTI patients whose diagnosed based on Society of
Obstetricians and Gynecologists of Canada and European Association of Urology criteria and
34 healthy young women, aged 15–50 years old, were included in this study. Risk factors and clin-
ical manifestations were evaluated and serum C3 levels were measured by ELISA. Correlations of
risk factors, clinical manifestation and C3 levels with recurrent UTI were analyzed with chi-square
test and Fisher’s exact test or t-test as appropriate with data.
36 M. Syukri et al.Results: This study found that some risk factors (age [p= 0.000], sexual intercourse frequency
[p= 0.00], marital status [p= 0.000] and intrauterine device contraception [p= 0.000]) and clinical
manifestations (fever [p= 0.000], dysuria [p= 0.000], frequent urination [p= 0.000], supra-pubic
discomfort [p= 0.000] and ﬂank pain [p= 0.006]) were correlated with recurrent UTI. Although
this study found that serum C3 levels were signiﬁcantly different between recurrent UTI patients
and healthy young women group (mean 42.08 lg/ml ± 1.20 vs 42.75 lg/ml ± 0.71, p= 0.008), this
difference is not clinically relevant.
Conclusion: In this study setting, the levels of C3 among young women with recurrent UTI were
lower than healthy women but were not signiﬁcant clinically.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Urinary tract infection (UTI) is one of the most common
bacterial infections.1 It is estimated that 150 million UTI
cases occur per year worldwide, resulting in high direct
health care expenditure.2 In general, UTI is self limiting,
but has a propensity to recur in particular conditions.3
Young women, even with normal function or anatomy of
the urinary tract, commonly suffer from UTI with an
estimated incidence of 0.5–0.7 infections per year and
25–30% will develop recurrent UTI.4 Recurrent UTI is an
episode of UTI which occurs at least two times in 6 months
or three or more re-infections in 12 months with clinical
symptoms. Recurrent UTI is one of the main causes of renal
scars and increases renal insufﬁciency, hypertension and
morbidity.
Some hypotheses suggest that recurrent UTI related to
host immunity, and activation of complement cascade is
one of the major immunity components. Activation of com-
plement cascade occurs via three distinct pathways (the clas-
sic, alternative, and mannan binding lectin) which can be
activated by invading organisms. Activation by any of these
pathways leads to form C3 and C5 convertases and as a
result it increases the production of biologically active com-
ponents including anaphylatoxins, opsonins, and membrane
attack complex.4,5
C3 plays a pivotal role in the complement cascade, solu-
bilization of immune complexes, bacterial killing through
opsonophagocytosis, formation of membrane attack com-
plex, and humoral immune response potentiation.6 However,
the role of C3 in recurrent UTI among young women is
debatable. Bacteria have been shown to use host immune
responses such as complement activation to its advantage
in invading the host cells. For example, a study found that
mice deﬁcient in C3 gene, when compared with wild-type
mice, had a lower infection rate upon inoculation with Esch-
erichia coli in the urinary bladder.7 Furthermore, the study
revealed that bacteria opsonization by C3 assisted bacteria
invasion to urinary tract cells4 and inhibition of complement
activation reduced tissue damage.7–10 However, studies con-
ﬁrmed that C3 deﬁcient individuals had higher susceptibility
to recurrent bacterial,6,11,12 fungal13 and viral14 infection.
Therefore, the aim of this study was to determine the associ-
ation between total serum C3 level and recurrent UTI among
young women.2. Materials and methods
2.1. Subjects
Thirty-four young women, aged 15–50 years old, with recur-
rent UTI which have been conﬁrmed and 34 healthy young
women were included in this study. Recurrent UTI criteria
based on Society of Obstetricians and Gynecologists of
Canada15,16 and European Association of Urology17 were
applied. Recurrent UTI criteria were: (a). Uncomplicated
UTI that occurred three times or more in 12 months or two
times or more in 6 months; (b). No structural and/or func-
tional abnormality of the urinary tract; (c). Mid-stream sample
of urine <103 cfu/mL of uropathogen, and (d). Infection was
conﬁrmed with mid-stream urine culture. Patients who hadP3
urinary symptoms such as dysuria, frequency, urgency,
hematuria, back pain, self-diagnosis of UTI, nocturia,
costovertebral angle tenderness were anamnesed for deeper
investigation. Patients with diabetes mellitus, liver cirrhosis,
immunosuppressive diseases, use of immunosuppressive drug,
pregnancy, post manipulated bladder, post catheterization,
post kidney transplant, and a negative urine culture result were
excluded from the study. Healthy young women group were
deﬁned as a group of women with no clinical symptom of
UTI in the last 3 years and had no sign and symptom of infec-
tion at the enrollment time of this study. Healthy young
women group consists of doctors, nurses and medical students.
The subject recruitment and sample collection were done only
after obtaining written informed consent of the participants.
The work was carried out in accordance with The Code of
the World Medical Association (Declaration of Helsinki) for
experiments involving humans.
2.2. ELISA for quantiﬁcation of total serum C3
During an episode of UTI –– after initial diagnose and before
any treatment –– vein blood samples of recurrent UTI patients
were collected. Blood samples from healthy young women
group were collected during no sign and symptom of infection.
Serums were prepared as described previously.18 Brieﬂy, 2.5 ml
blood from each participant was placed in an empty vacutainer
tube for serum preparation. Blood samples were allowed to
clot at room temperature for 2 h and then tubes were centri-
fuged. Serums were removed and stored at 70 C and used
before 3 months.
Comparison of serum C3 complement levels 37Serum C3 levels were measured by ELISA principle as
described previously.19 In brief, 96-well plates were coated
overnight at 4 C with 100 ml of sheep anti-human C3
diluted 1/200 in PBS. After washing, they were blocked with
PBS, 2% BSA, at 37 C for 1 h. Serum samples, diluted 1/
200,000 in sample buffer, were added in duplicate. Then rab-
bit anti-human C3 diluted 1/3000 in sample buffer (PBS, 2%
BSA, 0Æ05% Tween). After incubation at 37 C for 1 h,
horseradish peroxidase-conjugated goat anti-rabbit IgG
diluted 1/5000 in sample buffer. The enzyme activity was
read after incubation with o-phenylenediamine by measuring
absorbance at 490 nm. A pooled normal human serum of
known C3 concentration was used to generate a standard
curve.
2.3. Statistical analysis
Correlations of risk factors and clinical manifestations with
recurrent UTI were analyzed with chi-squared test and
Fisher’s exact test or Student’s t-test as appropriate with
data. Student’s t-test for comparison was used to compare
serum C3 levels between recurrent UTI and healthy young
women groups. Values of p 6 0.05 were regarded as
signiﬁcant.Table 1 Risk factors, clinical manifestation and C3 levels between
Variables Subjects
R-UTI
Risk factors
Marrieda
Yes 29
No 5
Intrauterine device (IUD)a
Yes 7
No 27
Age (years, mean)b 32
Sexual intercourse frequency (per week, mean)b 1.90
Clinical manifestation
Fevera
Yes 14
No 20
Dysuriaa
Yes 27
No 7
Hematuriaa
Yes 3
No 31
Frequent urinarya
Yes 20
No 14
Supra-pubic discomforta
Yes 20
No 14
Flank paina
Yes 7
No 27
C3 complement level
Serum C3 (lg/ml, mean)b 42.08
a Analyzed with chi-square and Fisher’s exact test.
b Analyzed with t-test. R-UTI, recurrent urinary tract infection; OR, o3. Results
3.1. Sample characteristic and risk factors
A total of 68 young women (34 patients with recurrent UTI,
mean age was 32 years old; 34 healthy women, mean age was
26.1 years old) were enrolled in this study. Risk factors of
recurrent UTI are presented in Table 1. Age (p= 0.000),
sexual intercourse frequency (p= 0.000), marital status
(OR = 13.9, 95% CI: 4.2–46.3) and intrauterine device contra-
ception (OR= 8.6, 95% CI: 0.9–73.9) were correlated with
recurrent UTI. In addition, this study found that recurrent
UTI had a signiﬁcant association with fever (OR = 2.7, 95%
CI: 1.9–3.8), dysuria (OR = 5.8, 95% CI: 2.9–11.5), frequent
urination (OR= 3.4, 95% CI: 2.2–5.3), supra-pubic discom-
fort (OR = 3.4, 95% CI: 2.2–5.3) and ﬂank pain (OR= 2.3,
95% CI: 1.7–2.9), but not with hematuria (p= 0.120).3.2. Serum C3 levels and recurrent UTI
Serum C3 concentrations were measured by using ELISE
microplate reader. The average concentrations of serum C3
in recurrent UTI were 42.08 lg/ml ± 1.20, while the averagerecurrent UTI patients and healthy young women.
OR (CI 95%) p
Control
13.9 (4.2–46.3) <0.001
10
24
8.6 (0.9–73.9) 0.027
1
33
26.10 <0.001
0.62 <0.001
2.7 (1.9–3.8) <0.001
0
34
5.8 (2.9–11.5) <0.001
0
34
2.1 (1.6–2.7) 0.120
0
34
3.4 (2.2–5.3) <0.001
0
34
3.4 (2.2–5.3) <0.001
0
34
2.3 (1.7–2.9) 0.006
0
34
42.75 0.008
dd ratio.
38 M. Syukri et al.concentrations of serum C3 among healthy young women were
42.75 lg/ml ± 0.71. Statistic analysis found that serum C3 lev-
els of recurrent UTI group and healthy young women group
were signiﬁcantly different (p= 0.008) as shown in Table 1.
Serum C3 concentrations from recurrent UTI patients and
healthy young women are presented in detail in Fig. 1.
4. Discussion
Previous studies found that there were several risk factors of
recurrent UTI such as sexual intercourse frequency, use of con-
traception (intrauterine device, diaphragm and spermicidal),
UTI history, use of antibiotic and estrogen, and the anatomy
of urinary tract.16,17,20–22 In a six-month cohort study by Fox-
man et al.23 it was found that recurrent UTI increased among
patients who had high intercourse frequency (OR = 1.6, 95%
CI: 1.2–2.1) and the usage of intrauterine contraception accep-
tor (OR = 1.5, 95% CI: 0.9–2.5). This study found that age,
marital status, sexual intercourse frequency and the usage of
intrauterine device were correlated with recurrent UTI.
Besides those risk factors, host immunity component might
be one of the important risk factors of recurrent UTI and one
of the important host immunity components is C3. Several
studies have been conducted to assess the role of C3 in
infectious diseases.6,11,13,14,24 Previous studies found that C3-
deﬁcient individuals tend to suffer from infections caused by
Streptococcus pneumoniae, Streptococcus pyogenes, Staphylo-
coccus aureus, Neisseria meningitidis, Haemophilus inﬂuenza,
Enterobacter aerogenes and E. coli.6,11,24 A study, by using
mice lacking C3 model, found that C3 was essential for Can-
dida albicans and Candida glabrata resistance and absence of
C3 impaired fungal clearance.13 In addition, another study
showed that C3 deﬁcient mice (C3/ mice) were highly sus-
ceptible to inﬂuenza virus, delayed viral clearance and
increased viral titers in the lungs.14 All of these evidences
reveal that C3-deﬁcient individuals have higher risk to be
infected by microorganisms and infection tends to be recurrent
and more severe.Figure 1 Comparison of serum C3 levels among recurrent UTI
patients and healthy young women.Although there is no study existing in terms of the role of
C3 in recurrent UTI, it seems that C3 has detrimental roles
in UTI, especially in ascending UTI. Evidence reveals that
within the urinary tract system, the presence of bacteria alone
is not sufﬁcient to cause ascending infection because bacteria
have to traverse urinary tract mucosal before infection can
become established. Bacteria might achieve this step by caus-
ing epithelial detachment or shedding, or by direct invasion
of the epithelial cells.7 Interestingly, this step might be corre-
lated with host complement activation. Studies found that
complement activation caused damage of host urinary tract
system tissues25,26 and inhibition of complement activation
reduced the inﬂammatory response and, therefore, reduced
the degree of tissues damage.7–10 In addition, study by Sprin-
gall et al.7 found that C3 deﬁciency protected mice from
ascending renal infection. Their study revealed that renal epi-
thelial cells internalized fewer bacteria in the absence of C3.
Moreover, bacteria might use host C3 to invade the renal epi-
thelium via the surface receptors Crry or CD46.7,27
These evidences seem to contradict each other. On one
hand, it is clear that C3 opsonizes bacteria, C3 deﬁciency leads
to ineffective clearance of the bacteria and causes severe infec-
tion and low serum C3 level increases risk factor for recurrent
infections. On the other hand, activation of C3 correlates with
higher urinary tract tissue damage and the rate of renal infec-
tion. The possible reason for this condition is C3 might have
bifunctional property that is dependent on its concentration,
similar to bifunctional property of some main cytokines.28
This study found that the levels of C3 among recurrent UTI
patients were signiﬁcantly lower compared with healthy young
women. As mentioned in previous studies, low C3 level was
one of the risk factors for viral, fungal and bacterial infec-
tions.6,11,13,14,24 However, in this study, the levels of C3 either
from recurrent UTI and healthy young women groups were
very low compared to C3 reference value29 and the difference
of C3 levels between recurrent UTI patients and healthy young
women were not signiﬁcant clinically.
Moreover, in this study, the blood samples from recurrent
UTI patients were collected during acute episodes of infection.
It means the comparison was made between symptomatic
recurrent UTI patients and asymptomatic healthy young
women. Previous study found that some cytokines, which were
produced during inﬂammation or infection such as interleukin-
1, interleukin-6, and tumor necrosis factor, inferred C3 synthe-
sis within days of the insult.29 Therefore, it seems that our
comparison in this study did not appropriate to draw conclu-
sions regarding the association of C3 as risk factor of recurrent
UTI but rather C3 dynamic the infection per se. To determine
the role of C3 as risk factor of recurrent UTI, serum C3 levels
of recurrent UTI patients should be measured after an UTI
acute period (during asymptomatic period). In addition, other
inﬂammatory biomarkers such as proinﬂammatory cytokines
and acute phase proteins are important to be measured in
order to determine whether the level of C3 in recurrent UTI
is correlated with inﬂammation process or not.
Interestingly, this study revealed that acute episode of UTI
among recurrentUTI patients did not increase C3 level. Because
C3 plays a central role in activation of classical and alternative
complement pathways; therefore, we speculate that complement
activation system is low in recurrent UTI. The other possible
reasons are complement level can fall to a very low level within
a few hours due to the development of immune complexes.29
Comparison of serum C3 complement levels 39This study is not, however, without limitations. First, in
this study, single nucleotide polymorphisms that can affect
C3 levels were not determined. Single nucleotide polymor-
phisms should be considerate because previous studies found
that serum C3 level was affected by the genetic make-up of
the individual.30,31 The others, the sample size of this study
was relatively small and urine C3 level was not measured.
Therefore, further study comparing C3 levels with our recom-
mendation design as mentioned before, with large sample size
is required to investigate the potential roles of C3 in recurrent
UTI.5. Conclusion
In conclusion, this study found serum C3 levels are lower
among young women with recurrent UTI compared to healthy
young women.
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